- US-listed companies
- Eloxx Pharmaceuticals, Inc.
- Income statement
Eloxx Pharmaceuticals, Inc. (ELOX) Income statement
Market cap
$92.08M
P/E ratio
| 2013/06 | 2014/06 | 2015/06 | 2016/06 | 2017/06 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2025/12 | |
| Research & development | 23 | 3 | 5 | 2 | 733,661 | 16 | 20 | 26 | 15 | - | - | - |
| Operating expenses | 59 | 9 | 18 | 11 | 5 | 20 | 48 | 51 | 33 | 66 | 34 | 6 |
| Operating income | -4,650,500 | -9,147,796 | -18,076,736 | -11,194,983 | -4,592,869 | -20 | -48 | -51 | -33 | -66 | -34 | -6 |
| Income before tax | - | - | - | -8,947,929 | -6,836,363 | - | -47 | -51 | -35 | - | - | - |
| Provision for income taxes | - | - | - | -680,000 | -1,040,000 | - | 0 | - | - | - | - | - |
| Effective tax rate (%) | - | - | - | - | - | - | - | - | - | |||
| Net income | -6,122,542 | -9,225,234 | -18,063,785 | -8,267,929 | -5,796,363 | -21 | -47 | -51 | -35 | -67 | -36 | -6 |
| Earnings per share | - | - | - | - | - | - | - | - | - | - | -16.65 | -0.49 |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -16.65 | -0.49 |